Nanomedicines for the Treatment of CNS Diseases

Jessica L. Reynolds, Ram I Mahato

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Targeting and delivering macromolecular therapeutics to the central nervous system (CNS) has been a major challenge. The blood–brain barrier (BBB) is the main obstacle that must be overcome to allow compounds to reach their targets in the brain. Therefore, much effort has been channelled into improving transport of therapeutics across the BBB and into the CNS including the use of nanoparticles. In this thematic issue, several reviews and original research are presented that address “Nanomedicines for CNS Diseases.” The articles in this issue are concentrated on either CNS-HIV disease or CNS tumors. In regards to CNS-HIV disease, there are two reviews that discuss the role of nanoparticles for improving the delivery of HIV therapeutics to the CNS. In addition, there are two original articles focusing on therapies for CNS-HIV, one of them uses nanoparticles for delivery of siRNA specific to a key protein in autophagy to microglia, and another discusses nanoparticle delivery of a soluble mediator to suppress neuroinflammation. Furthermore, a comprehensive review about gene therapy for CNS neurological diseases is also included. Finally, this issue also includes review articles on enhanced drug targeting to CNS tumors. These articles include a review on the use of nanoparticles for CNS tumors, a review on functionalization (ligands) of nanoparticles for drug targeting to the brain tumor by overcoming BBB, and the final review discusses the use of macrophages as a delivery vehicle to CNS tumors. This thematic issue provides a wealth of knowledge on using nanomedicines for CNS diseases.

Original languageEnglish (US)
JournalJournal of Neuroimmune Pharmacology
Volume12
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Nanomedicine
Central Nervous System Diseases
Nanoparticles
Central Nervous System Neoplasms
Central Nervous System
HIV
Drug Delivery Systems
Therapeutics
Autophagy
Microglia
Brain Neoplasms
Genetic Therapy
Small Interfering RNA
Macrophages
Ligands
Brain
Research

Keywords

  • CNS
  • Cancer
  • HIV
  • Nanomedicine

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Nanomedicines for the Treatment of CNS Diseases. / Reynolds, Jessica L.; Mahato, Ram I.

In: Journal of Neuroimmune Pharmacology, Vol. 12, No. 1, 01.03.2017.

Research output: Contribution to journalArticle

@article{7b6fbda046e747979a0acb4b8e8d9749,
title = "Nanomedicines for the Treatment of CNS Diseases",
abstract = "Targeting and delivering macromolecular therapeutics to the central nervous system (CNS) has been a major challenge. The blood–brain barrier (BBB) is the main obstacle that must be overcome to allow compounds to reach their targets in the brain. Therefore, much effort has been channelled into improving transport of therapeutics across the BBB and into the CNS including the use of nanoparticles. In this thematic issue, several reviews and original research are presented that address “Nanomedicines for CNS Diseases.” The articles in this issue are concentrated on either CNS-HIV disease or CNS tumors. In regards to CNS-HIV disease, there are two reviews that discuss the role of nanoparticles for improving the delivery of HIV therapeutics to the CNS. In addition, there are two original articles focusing on therapies for CNS-HIV, one of them uses nanoparticles for delivery of siRNA specific to a key protein in autophagy to microglia, and another discusses nanoparticle delivery of a soluble mediator to suppress neuroinflammation. Furthermore, a comprehensive review about gene therapy for CNS neurological diseases is also included. Finally, this issue also includes review articles on enhanced drug targeting to CNS tumors. These articles include a review on the use of nanoparticles for CNS tumors, a review on functionalization (ligands) of nanoparticles for drug targeting to the brain tumor by overcoming BBB, and the final review discusses the use of macrophages as a delivery vehicle to CNS tumors. This thematic issue provides a wealth of knowledge on using nanomedicines for CNS diseases.",
keywords = "CNS, Cancer, HIV, Nanomedicine",
author = "Reynolds, {Jessica L.} and Mahato, {Ram I}",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s11481-017-9725-x",
language = "English (US)",
volume = "12",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Nanomedicines for the Treatment of CNS Diseases

AU - Reynolds, Jessica L.

AU - Mahato, Ram I

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Targeting and delivering macromolecular therapeutics to the central nervous system (CNS) has been a major challenge. The blood–brain barrier (BBB) is the main obstacle that must be overcome to allow compounds to reach their targets in the brain. Therefore, much effort has been channelled into improving transport of therapeutics across the BBB and into the CNS including the use of nanoparticles. In this thematic issue, several reviews and original research are presented that address “Nanomedicines for CNS Diseases.” The articles in this issue are concentrated on either CNS-HIV disease or CNS tumors. In regards to CNS-HIV disease, there are two reviews that discuss the role of nanoparticles for improving the delivery of HIV therapeutics to the CNS. In addition, there are two original articles focusing on therapies for CNS-HIV, one of them uses nanoparticles for delivery of siRNA specific to a key protein in autophagy to microglia, and another discusses nanoparticle delivery of a soluble mediator to suppress neuroinflammation. Furthermore, a comprehensive review about gene therapy for CNS neurological diseases is also included. Finally, this issue also includes review articles on enhanced drug targeting to CNS tumors. These articles include a review on the use of nanoparticles for CNS tumors, a review on functionalization (ligands) of nanoparticles for drug targeting to the brain tumor by overcoming BBB, and the final review discusses the use of macrophages as a delivery vehicle to CNS tumors. This thematic issue provides a wealth of knowledge on using nanomedicines for CNS diseases.

AB - Targeting and delivering macromolecular therapeutics to the central nervous system (CNS) has been a major challenge. The blood–brain barrier (BBB) is the main obstacle that must be overcome to allow compounds to reach their targets in the brain. Therefore, much effort has been channelled into improving transport of therapeutics across the BBB and into the CNS including the use of nanoparticles. In this thematic issue, several reviews and original research are presented that address “Nanomedicines for CNS Diseases.” The articles in this issue are concentrated on either CNS-HIV disease or CNS tumors. In regards to CNS-HIV disease, there are two reviews that discuss the role of nanoparticles for improving the delivery of HIV therapeutics to the CNS. In addition, there are two original articles focusing on therapies for CNS-HIV, one of them uses nanoparticles for delivery of siRNA specific to a key protein in autophagy to microglia, and another discusses nanoparticle delivery of a soluble mediator to suppress neuroinflammation. Furthermore, a comprehensive review about gene therapy for CNS neurological diseases is also included. Finally, this issue also includes review articles on enhanced drug targeting to CNS tumors. These articles include a review on the use of nanoparticles for CNS tumors, a review on functionalization (ligands) of nanoparticles for drug targeting to the brain tumor by overcoming BBB, and the final review discusses the use of macrophages as a delivery vehicle to CNS tumors. This thematic issue provides a wealth of knowledge on using nanomedicines for CNS diseases.

KW - CNS

KW - Cancer

KW - HIV

KW - Nanomedicine

UR - http://www.scopus.com/inward/record.url?scp=85011298813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011298813&partnerID=8YFLogxK

U2 - 10.1007/s11481-017-9725-x

DO - 10.1007/s11481-017-9725-x

M3 - Article

VL - 12

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 1

ER -